ABVX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

144.540

Open

141.900

VWAP

143.29

Vol

482.28K

Mkt Cap

11.49B

Low

141.000

Amount

69.11M

EV/EBITDA(TTM)

--

Total Shares

79.77M

EV

20.83B

EV/OCF(TTM)

--

P/S(TTM)

--

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Show More

Events Timeline

(ET)

2026-07-01

09:30:00

Increased Deal Size to $800M in Common Stock

2026-07-01

08:30:00

Leerink, Morgan Stanley, and Others Jointly Manage Offering

2026-06-30 (ET)

2026-06-30

17:30:00

Leerink, Morgan Stanley, and Others Jointly Manage New Stock Offering

2026-06-30

17:00:00

Abivax SA Launches Underwritten Public Offering of Approximately $600M

2026-06-30

16:30:00

Major Averages Broadly Higher to Close Q2

2026-06-30

12:30:00

Abivax Stock Rises 35.8% to $130.55

2026-06-30

12:30:00

Major Averages Rise as S&P 500 and Nasdaq Rebound

News

seekingalpha

07-02seekingalpha

Abivax Completes $920M Public Offering with Full Underwriter Option Exercise

stocktwits

07-02stocktwits

Abivax Increases Offering to 7.36 Million Shares, Raising $874.1 Million

Newsfilter

07-02Newsfilter

Abivax Fully Exercises Underwriters' Option for Additional ADS Purchase

stocktwits

07-01stocktwits

Abivax Raises $800 Million Through ADS Offering

NASDAQ.COM

07-01NASDAQ.COM

ABIVAX Prices Public Offering of 6.4 Million ADSs

Newsfilter

07-01Newsfilter

Abivax Prices Oversubscribed $800M Public Offering

8 Analyst Rating

Wall Street analysts forecast ABVX stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Current: 0.000

Low

131.00

Averages

150.71

High

175.00

Truist

Buy

maintain

$135 -> $155

AI Analysis

2026-07-02

New

Reason

Truist

Price Target

$135 -> $155

AI Analysis

2026-07-02

New

maintain

Buy

Reason

Truist raised the firm's price target on Abivax to $155 from $135 and keeps a Buy rating on the shares. ollowing maintenance Part 2 data, discussions with Abivax management reinforced confidence that obefazimod's safety profile supports a Q4 ulcerative colitis NDA submission, while opportunities in combination therapy, Crohn's disease, and strategic activity provide additional upside beyond the core ulcerative colitis approval thesis, the analyst tells investors in a research note.

Jefferies

Faisal Khurshid

Hold

to

Buy

upgrade

$108 -> $158

2026-06-30

Reason

Jefferies

Faisal Khurshid

Price Target

$108 -> $158

2026-06-30

upgrade

Hold

to

Buy

Reason

Jefferies analyst Faisal Khurshid upgraded Abivax to Buy from Hold with a price target of $158, up from $108.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABVX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Abivax SA (ABVX.O) is 0.00, compared to its 5-year average forward P/E of -10.13. For a more detailed relative valuation and DCF analysis to assess Abivax SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-10.13

Current PE

0.00

Overvalued PE

-0.23

Undervalued PE

-20.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-14.39

Current EV/EBITDA

-3.13

Overvalued EV/EBITDA

13.71

Undervalued EV/EBITDA

-42.49

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

281.88

Current PS

130.84

Overvalued PS

966.11

Undervalued PS

-402.34

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks gain $5.00 in 2026

Intellectia · 2622 candidates

Year Price Change Pct: >= $0.01

Ticker

Name

Market Cap$

AXT Inc

3.80B

Palatin Technologies Inc

35.18M

Regencell Bioscience Holdings Ltd

12.08B

Relmada Therapeutics Inc

639.83M

Babcock & Wilcox Enterprises Inc

1.95B

Terns Pharmaceuticals Inc

5.44B

ابي سهم التارقت حقي يكون اجيب فوق 25% واعلى من راس مالي

Intellectia · 1346 candidates

Year Price Change Pct: >= $25.00

Ticker

Name

Market Cap$

Regencell Bioscience Holdings Ltd

13.54B

Palatin Technologies Inc

28.78M

Rich Sparkle Holdings Ltd

875.38M

Abivax SA

8.86B

Sandisk Corp

97.55B

Hycroft Mining Holding Corporation

3.20B

what stocks is up more than 500%

Intellectia · 22 candidates

Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $500.00

Ticker

Name

Market Cap$

Sandisk Corp

73.47B

Regencell Bioscience Holdings Ltd

10.83B

Abivax SA

9.41B

Celcuity Inc

4.96B

Terns Pharmaceuticals Inc

3.99B

Hycroft Mining Holding Corporation

3.22B

Whales Holding ABVX

VR Management, LLC

Paradigm Biocapital Advisors LP

Logos Global Management, L.P.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.

BVF Partners L.P.

Fred Alger Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Abivax SA (ABVX) stock price today?

The current price of ABVX is 144.32 USD — it has increased 0.23

What is Abivax SA (ABVX)'s business?

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

What is the price predicton of ABVX Stock?

Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is150.71 USD with a low forecast of 131.00 USD and a high forecast of 175.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Abivax SA (ABVX)'s revenue for the last quarter?

Abivax SA revenue for the last quarter amounts to NaN USD, decreased

What is Abivax SA (ABVX)'s earnings per share (EPS) for the last quarter?

Abivax SA. EPS for the last quarter amounts to USD, decreased

How many employees does Abivax SA (ABVX). have?

Abivax SA (ABVX) has 0 emplpoyees as of July 07 2026.

What is Abivax SA (ABVX) market cap?

Today ABVX has the market capitalization of 11.49B USD.